Document Detail


The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
MedLine Citation:
PMID:  23410027     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to determine the effects of the histone deacetylase inhibitor, MS-275, on the Fas signaling pathway and susceptibility of osteosarcoma (OS) to Fas ligand (FasL)-induced cell death. OS metastasizes almost exclusively to the lungs. We have shown that Fas expression in OS cells is inversely correlated with their metastatic potential. Fas(+) cells are rapidly eliminated when they enter the lungs via interaction with FasL, which is constitutively expressed in the lungs. Fas(-) OS cells escape this FasL-induced apoptosis and survive in the lung microenvironment. Moreover, upregulation of Fas in established OS lung metastases results in tumor regression. Therefore, agents that upregulate Fas expression or activate the Fas signaling pathway may have therapeutic potential. Treatment of Fas(-) metastatic OS cell lines with 2 µM MS-275 sensitized cells to FasL-induced cell death in vitro. We found that MS-275 did not alter the expression of Fas on the cell surface; rather it resulted in the downregulation of the anti-apoptotic protein, c-FLIP (cellular FLICE-inhibitory protein), by inhibiting c-FLIP mRNA. Downregulation of c- FLIP correlated with caspase activation and apoptosis induction. Treatment of nu/nu-mice with established OS lung metastases with oral MS-275 resulted in tumor regression, increased apoptosis and a significant inhibition of c-FLIP expression in tumors. Histopathological examination of mice showed no evidence of significant toxicity. Overall, these results suggest that the mechanism by which MS-275 sensitizes OS cells and lung metastases to FasL-induced cell death may be by a direct reduction in the expression of c-FLIP.
Authors:
Krithi Rao-Bindal; Nadezhda V Koshkina; John Stewart; Eugenie S Kleinerman
Related Documents :
23915297 - Cudrania cochinchinensis attenuates amyloid beta protein-mediated microglial activation...
24291067 - Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local su...
24929887 - Mita/sting: a central and multifaceted mediator in innate immune response.
21112917 - Preliminary analysis of the anti-inflammatory activity of essential oils of zingiber ze...
23477737 - Recruitment of beneficial m2 macrophages to injured spinal cord is orchestrated by remo...
9527927 - Influence of mucosal and parenteral immunization with a replication-defective mutant of...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current cancer drug targets     Volume:  13     ISSN:  1873-5576     ISO Abbreviation:  Curr Cancer Drug Targets     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-05-16     Completed Date:  2014-01-07     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  101094211     Medline TA:  Curr Cancer Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  411-22     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antigens, CD95 / genetics,  metabolism
Antineoplastic Agents / pharmacology
Apoptosis / drug effects
Benzamides / pharmacology*
Blotting, Western
Bone Neoplasms / genetics,  pathology,  prevention & control*
CASP8 and FADD-Like Apoptosis Regulating Protein / genetics,  metabolism*
Cell Proliferation / drug effects
Fas Ligand Protein / genetics,  metabolism*
Humans
Immunoenzyme Techniques
Lung Neoplasms / genetics,  prevention & control*,  secondary
Mice
Mice, Nude
Osteosarcoma / genetics,  pathology,  prevention & control*
Pyridines / pharmacology*
RNA, Messenger / genetics
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Tumor Cells, Cultured
Grant Support
ID/Acronym/Agency:
CA16672/CA/NCI NIH HHS; CA42992/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS; R01 CA42992/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antigens, CD95; 0/Antineoplastic Agents; 0/Benzamides; 0/CASP8 and FADD-Like Apoptosis Regulating Protein; 0/Fas Ligand Protein; 0/Pyridines; 0/RNA, Messenger; 0/entinostat
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multifunctional surfaces with outstanding mechanical stability on glass substrates by simple H2SiF6-...
Next Document:  Pivotal role of the muscle-contraction pathway in cryptorchidism and evidence for genomic connection...